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Nevirapine (NVP), a non-nucleoside reverse transcriptase
inhibitor (NNRTI) used in human immunodeficiency
virus (HIV) treatment can cause hypersensitivity reactions
in 6-10% of patients, which in the most serious cases
(1.3%) can manifest as Stevens-Johnson Syndrome (SJS)
or Toxic Epidermal Necrolysis (TEN). A total of 209
patients with NVP hypersensitivity (57 from a prospective
cohort and 152 clinic patients) were compared with 463
control patients on NVP without any hypersensitivity.
The case group included 70 patients with serious blistering
reactions (SJS or TEN). All individuals were genotyped for
2 SNPs in the CYP2B6 gene (c.516G>T [CYP2B6*9] and
c.983T>C [CYP2B6*18]) using the TaqMan real-time gen-
otyping platform. A replication cohort of 29 controls and
31 nevirapine hypersensitive patients, including 8 SJS/TEN
cases, was subsequently typed. An association between the
CYP2B6*18 polymorphism and NVP-induced SJS/TEN
was observed (p=0.013). In the SJS/TEN group, 30% of
individuals possessed at least one *18 allele vs. 16% in the
tolerant group (p=0.006; OR (95% CI) 2.24(1.27-3.94)).
This association was also borderline significant in the
replication cohort (p=0.075). Combined analysis resulted
in an odds ratio of 2.52 (95% CI 1.48-4.20; p=0.0005) for
the association of SJS/TEN with CYP2B6*18. This
association was not observed for other hypersensitivity
phenotypes. Data show a putative association between the
CYP2B6*18 polymorphism and nevirapine-induced SJS/
TEN. CYP2B6*18 has a frequency of around 5-10% in
African populations but is not observed in Caucasians,
and this may therefore represent an ethnicity-specific
predisposing factor.
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